Adeela Kamal

Actinium Pharmaceuticals is focused on developing innovative targeted radiotherapeutics for the treatment of advanced cancers.

• Provide R&D consulting services for Drug Discovery, Translational Medicine, and Early Clinical Development to support target discovery, lead generation, Development Candidates, IND filings and clinical biomarkers. • Served as fractional Chief Scientific Officer to early-stage biotech companies to guide portfolio strategy, build preclinical teams, forecast R&D budgets and acquire/start new lab facilities. • Advised C-level, boards and investors on R&D programs in Discovery and Early Development.

• Built from ground-up and led Preclinical and Translational Medicine functional areas (Discovery Biology, DMPK, Toxicology, Clinical Biomarkers and Translational Bioinformatics) for advancing targeted Oncology programs. • Established infrastructure and capabilities: AOP/LRP budgets, lab site acquisition/upfitting, recruitment of functional leaders and research staff. • Guided small molecule Oncology programs from LI/LO to Development Candidate nomination, IND filing and provided clinical biomarker support. • Presented at company scientific board meetings and external scientific conferences as invited speaker. • Contributed to business development efforts by conducting due diligence. • Founding member and co-chair of the Women's Employee Resource Group, fostering women leadership, mentorship, external HBA partnerships, International Women's Day and Womens Equality Day programs.

• Led R&D departments in US/Canada for Pipeline Research, Antibody Lead Generation, PK/PD, Nonclinical Safety, Bioanalytical Development (GLP), Process Development (GMP) and Product Development Team Leaders (PDTLs). • Developed the R&D strategy for the Therapeutics Business Unit; presented at Board Meetings • Responsible for biologics R&D portfolio from preclinical to Ph 3 including AOP/LRP budgets. • Established and implemented governance process for stage-gate decisions for R&D programs; chair of Early Portfolio Steering Committee (preclinical to end Phase 2). • Evaluated and provided due diligence for in-licensing opportunities aligned with Business Unit strategy.

• Formulated global therapeutic area (TA) long-term strategies and built Uro-Oncology portfolio of biologics. • Built new Translational Research capabilities including bioinformatics in all TA’s (Uro-Oncology, Gastroenterology and Reproductive Medicine). • Led experimental scientists for establishing new project ideas through design and execution of experiments from preclinical into the clinic. • Designed clinical biomarker plans for Ph 3 asset in bladder cancer and supported BLA filing. Collaborated globally with Clinical (Copenhagen), Medical Affairs (New Jersey) and Commercial (St Prex) for TPP, LCM and product launch plans. • Member of Portfolio Committee for portfolio governance and R&D Strategic Leadership Team. • Evaluated and recommended in-licensing opportunities; broadened portfolio aligned to TA strategy. • Member of Ferring Women’s Council; led programming at San Diego site for HBA and Women in Bio.

• Directed team of scientists and advanced Oncology antibody programs at MedImmune (biologics unit of AstraZeneca) from discovery into IND filing and clinical trials. • Research Lead in cross-functional Product Development Teams (PDTs) including supporting BLA filing. • Championed development of internal Antibody Drug Conjugate (ADC) platform that resulted in 13 new Oncology ADC programs within 2 years. • Governed 20+ programs as member of Oncology Research Review Committee in Maryland/US and Cambridge/UK. • Evaluated and recommended in-licensing opportunities including $440M acquisition of Spirogen. • Established and led >15 academic collaborations (including establishing 2 umbrella CRADAs with the NIH for ADCs and immune-oncology programs).

(Biogen acquired Conforma Therapeutics) • Led Ph.D. Scientists/Research Associates for target identification and validation, lead optimization, and development candidate nomination for small molecule Oncology programs. • Project Leader of cross-functional teams (Pharmacology, Medicinal Chemistry, ADME/DMPK, Clinical) for small molecule programs targeting cell cycle, tumor growth and survival. • Evaluated external in-licensing opportunities for Business Development. • Identified new Oncology targets as member of Target Selection Committee.

• Led selection of first small molecule clinical candidate for Oncology and contributed to IND filing at start-up biotech. • Hired and trained Scientists/Research Associates to meet all compound screening objectives. • Published first-author Nature paper validating company's first drug target in Oncology. • Established innovative screening program for identification of kinase inhibitors for Oncology. • Identified and managed 20+ external collaborations for indication expansion in Neuroscience and Infectious diseases. • Presented in-house research programs to potential industry partners leading to the $250M acquisition of Conforma by Biogen IDEC.